Estamos no ar no ! Saiba mais
ícone de TNDM

Tandem Diabetes Care

16,24 USD
-0,28
1,69%
No fechamento Atualizado 16 de out. 16:00 EDT
1 dia
-1,69%
5 dias
0,81%
1 mês
-7,36%
3 meses
-0,31%
6 meses
-19,16%
No acumulado do ano
-24,64%
1 ano
6,21%
5 anos
-86,77%
10 anos
-75,39%
 

Sobre: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

Funcionários: 2.500

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 35,7%
Neutro 50%
Negativo 14,3%
Neutro
Zacks Investment Research
há 7 dias
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Neutro
Business Wire
há 15 dias
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diab.
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Neutro
Business Wire
há 19 dias
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Positivo
Zacks Investment Research
há 29 dias
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Neutro
Zacks Investment Research
mês passado
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Positivo
Benzinga
mês passado
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
Positivo
MarketBeat
há 2 meses
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Negativo
Zacks Investment Research
há 2 meses
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Positivo
MarketBeat
há 2 meses
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Tandem Diabetes Care Q2 Earnings Call Highlights
Neutro
Seeking Alpha
há 2 meses
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Gráficos de preços implementados com Lightweight Charts™